All In Biotech

Drug Trial Radar · NCT06456528

QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia

Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia.

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 235 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

235

Planned (sponsor's estimate)

Start

Oct 22, 2024

Primary completion

Apr 30, 2027

Study completion Jul 30, 2027

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.

Conditions

  • Cancer Treatment-Induced Thrombocytopenia

Interventions

  • QL0911Drug

    QL0911

  • QL0911 plus PlaceboDrug

    QL0911 plus Placebo

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of treatment responders.Time frame: Randomization up to 80 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Harbin First Hospital

    Harbin, China · Recruiting

  • Nanjing Tianyinshan Hospital

    Nanjing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.